Differential Immune Effects of Natalizumab
Completed
- Conditions
- Multiple Sclerosis, Relapsing Remitting
- Registration Number
- NCT00859482
- Lead Sponsor
- Cantonal Hospital of St. Gallen
- Brief Summary
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.
- Detailed Description
Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- relapsing remitting MS
- indication for natalizumab treatment
Exclusion Criteria
- other disease modifying agents within 2 weeks
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Function of T regulatory cells at month 3
- Secondary Outcome Measures
Name Time Method Change in distinct immune cell lines month 3